<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03828019</url>
  </required_header>
  <id_info>
    <org_study_id>9196</org_study_id>
    <nct_id>NCT03828019</nct_id>
  </id_info>
  <brief_title>Adalimumab vs. Conventional Immunosuppression for Uveitis Trial</brief_title>
  <acronym>ADVISE</acronym>
  <official_title>Adalimumab vs. Conventional Immunosuppression for Uveitis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding&#xD;
      diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and&#xD;
      immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α&#xD;
      monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior&#xD;
      corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is&#xD;
      multicenter randomized, parallel-treatment, comparative effectiveness trial comparing&#xD;
      adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in&#xD;
      the treatment of non-infectious, intermediate, posterior, and panuveitides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract from protocol: The uveitides are a collection of diseases characterized by&#xD;
      intraocular inflammation. Collectively, they are the 5th leading cause of blindness in the&#xD;
      US, and the estimated cost of treating them is similar to that of treating diabetic&#xD;
      retinopathy. Non-infectious intermediate, posterior, and panuveitides have the highest rates&#xD;
      of visual loss and typically are treated with oral corticosteroids and immunosuppression. The&#xD;
      Multicenter Uveitis Steroid Treatment (MUST) Trial (a randomized, comparative effectiveness&#xD;
      trial, which compared 2 treatment paradigms for these diseases, systemic therapy with&#xD;
      corticosteroids and immunosuppression vs. regional therapy [the fluocinolone acetonide&#xD;
      implant]), and Follow-up Study demonstrated the superiority of the systemic approach to the&#xD;
      regional ocular approach in terms of long-term visual outcomes with essentially no increase&#xD;
      in systemic side effects in the systemic group. One key to systemic therapy's success was the&#xD;
      use of systemic immunosuppression in 88% of participants, coupled with tapering the&#xD;
      prednisone to &lt;7.5 mg/day, a relatively safe dose. Non-alklyating agents are typically the&#xD;
      first choice and the most often used are azathioprine, methotrexate, mycophenolate,&#xD;
      cyclosporine, and tacrolimus. The alkylating agents, cyclophosphamide and chlorambucil, are&#xD;
      used less often because of concerns about potential increased malignancy risk. Data from the&#xD;
      Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study suggest that each of&#xD;
      the conventional, non-alkylating agent immunosuppressive drugs is effective in controlling&#xD;
      the inflammation while permitting tapering prednisone in ~40-55% of patients; hence&#xD;
      combination therapy often is needed. Furthermore, minimizing the daily dose of prednisone is&#xD;
      important, as the risk of cardiovascular disease and mortality increase with the cumulative&#xD;
      dose of oral corticosteroids. In June 2016, the fully-human, anti-TNF-α monoclonal antibody,&#xD;
      adalimumab, was approved by the US Food and Drug Administration (FDA) for the treatment of&#xD;
      uveitis. Anti-TNF-α monoclonal antibody therapy has revolutionized the management of the&#xD;
      rheumatic diseases largely due to its superior efficacy compared to conventional Disease&#xD;
      Modifying Anti-Rheumatic Drugs. Data from VISUAL III, the extension of the two phase 3 trials&#xD;
      that led to the FDA approval of adalimumab for the treatment of uveitis, suggest that&#xD;
      adalimumab may be superior to conventional immunosuppression, as ~75% of participants had&#xD;
      controlled inflammation with prednisone doses &lt;5 mg/day. The ADalimumab Vs. conventional&#xD;
      ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial&#xD;
      comparing adalimumab to conventional agent immunosuppression for patients with&#xD;
      non-infectious, intermediate, posterior, and panuveitides. The primary outcome is the ability&#xD;
      to successfully taper prednisone to &lt;7.5 mg/day by 6 months after randomization while&#xD;
      maintaining control of the inflammation. Secondary outcomes include prednisone&#xD;
      discontinuation by 1 year, visual acuity, and complications of uveitis and its treatment.&#xD;
&#xD;
      ADVISE is being conducted under IND 132532. Adalimumab was FDA approved for the treatment of&#xD;
      non-infectious intermediate, posterior, and panuveitides in adult patients in 2016 and in&#xD;
      pediatric patients 2 years of age and older in 2018. In 2016, prior to the approval for&#xD;
      pediatric patients, the FDA determined that use of adalimumab for the treatment of&#xD;
      non-infectious intermediate, posterior, and panuveitides in adolescent patients in the ADVISE&#xD;
      Trial does not increase risk for these patients as the drug is approved for treatment of&#xD;
      pediatric patients for other indications. Although conventional immunosuppressive drugs are&#xD;
      the standard approach and in widespread use, these drugs are not FDA approved for treatment&#xD;
      of non-infectious intermediate, posterior, and panuveitides, and therefore an IND has been&#xD;
      issued for this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized treatment assignment with allocation ratio: 1:1 and two stratification variables: (1) number of immunosuppressive drug patient is on at time of enrollment (zero vs. one); (2) Initial dose of prednisone patient will be on in trial (&lt;30 mg/day vs. ≥30 mg/day). The unit of randomization is the patient,</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Unmasked treatment administration and outcome assessments (participants, study ophthalmologists, visual function examiners, and study coordinators are all unmasked). Masked assessment of baseline, 1-month, 3-month, and 6-month photographic images and OCT by the Reading Center (graders masked).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Corticosteroid-sparing treatment success within the first 6 months after randomization</measure>
    <time_frame>6 months</time_frame>
    <description>Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits &gt;= 28 days apart while on &lt;= 7.5 mg/day of corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid-sparing treatment success within the first 12 months after randomization</measure>
    <time_frame>12 months</time_frame>
    <description>Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits &gt;= 28 days apart while on &lt;= 7.5 mg/day of corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prednisone discontinuation success</measure>
    <time_frame>12 months</time_frame>
    <description>Prednisone discontinuation success is defined as achieving inactive uveitis for two consecutive visits &gt;= 28 days apart after discontinuing corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prednisone exposure</measure>
    <time_frame>12 months</time_frame>
    <description>E.g., cumulative prednisone dose and/or mean prednisone dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity measured after a standardized refraction using logarithmic visual acuity charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of infections over 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Systemic adverse events over 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular edema</measure>
    <time_frame>12 months</time_frame>
    <description>Macular edema over 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility</measure>
    <time_frame>12 months</time_frame>
    <description>Health utility will be measured using the EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic health-related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Generic health-related quality of life will be measured using the SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Vision-related quality of life will be measured using the NEI-VFQ-25</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab (ADA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.&#xD;
Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents &lt;30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional immunosuppression (CON)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.&#xD;
Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab (ADA)</intervention_name>
    <description>Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.</description>
    <arm_group_label>Adalimumab (ADA)</arm_group_label>
    <other_name>Adalimumab, Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional immunosuppression (CON)</intervention_name>
    <description>The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.</description>
    <arm_group_label>Conventional immunosuppression (CON)</arm_group_label>
    <other_name>Azathioprine, Imuran , Cyclosporine</other_name>
    <other_name>Methotrexate, Rheumatrex</other_name>
    <other_name>Mycophenolate, CellCept</other_name>
    <other_name>Cyclosporine, Sandimmune, Neoral</other_name>
    <other_name>Tacrolimus, Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Age 13 years or older&#xD;
&#xD;
          2. Weight 30 kg (66 lbs) or greater&#xD;
&#xD;
          3. Active or recently active (≤ 60 days) non-infectious intermediate, posterior, or&#xD;
             panuveitis&#xD;
&#xD;
          4. Prednisone indication meets one of the following:&#xD;
&#xD;
               1. Active uveitis requiring one of the following i. Initiation of prednisone at dose&#xD;
                  greater than 7.5 mg/day ii. Increasing prednisone dose to greater than 7.5 mg/day&#xD;
                  iii. Currently receiving dose greater than 7.5 mg/day&#xD;
&#xD;
               2. Inactive uveitis on current dose greater 7.5 mg/day&#xD;
&#xD;
          5. Initiation or addition of an immunosuppressive drug (i.e., a conventional&#xD;
             immunosuppressive drug or adalimumab) is indicated&#xD;
&#xD;
          6. If currently receiving a conventional immunosuppressive drug, the drug and dose have&#xD;
             been stable for at least 30 days&#xD;
&#xD;
          7. Patient able and willing to self-administer subcutaneous injections or have a&#xD;
             qualified person available to administer subcutaneous injections&#xD;
&#xD;
          8. If posterior segment disease is present, ability to assess activity in at least one&#xD;
             eye with uveitis&#xD;
&#xD;
          9. Visual acuity of light perception or better in at least one eye with uveitis&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-γ&#xD;
             release assay [IGRA] test, such as Quantiferon-gold)&#xD;
&#xD;
          2. Untreated active hepatitis B or C infection&#xD;
&#xD;
          3. Any of the following baseline lab values&#xD;
&#xD;
               1. White blood count &lt;3500 cells per microliter&#xD;
&#xD;
               2. Platelets &lt;100,000 per microliter&#xD;
&#xD;
               3. Hematocrit &lt;30%&#xD;
&#xD;
               4. AST or ALT &gt;1.5X upper limit normal value&#xD;
&#xD;
               5. Serum creatinine &gt;1.1X upper limit normal value&#xD;
&#xD;
          4. Behçet disease&#xD;
&#xD;
          5. Multiple sclerosis or other demyelinating disease&#xD;
&#xD;
          6. For patients with anterior/intermediate or intermediate uveitis without systemic&#xD;
             disease, abnormal magnetic resonance imaging (MRI) of the brain consistent with&#xD;
             demyelinating disease&#xD;
&#xD;
          7. Severe uncontrolled infection&#xD;
&#xD;
          8. Receipt of a live vaccine within past 30 days&#xD;
&#xD;
          9. Moderate to severe heart failure (NYHA class III/IV)&#xD;
&#xD;
         10. Active malignancy&#xD;
&#xD;
         11. Use of anti-TNF monoclonal antibody therapy within past 60 days&#xD;
&#xD;
         12. History of adalimumab intolerance or ineffectiveness&#xD;
&#xD;
         13. Hypersensitivity to any of the study treatments or their excipients&#xD;
&#xD;
         14. Current treatment with an alkylating agent&#xD;
&#xD;
         15. Current treatment with more than one immunosuppressive drug, not including oral&#xD;
             corticosteroids&#xD;
&#xD;
         16. Shorter-acting regional corticosteroids administered within the past 30 days in any&#xD;
             eye(s) with uveitis&#xD;
&#xD;
         17. Long-acting ocular corticosteroid implants, i.e., fluocinolone acetonide implant&#xD;
             (e.g., Retisert®, YutiqTM, Iluvien®) placed within past 3 years unless uveitis is&#xD;
             active in all eye(s) with an implant&#xD;
&#xD;
         18. Systemic disease that is sufficiently active such that it dictates therapy with&#xD;
             systemic corticosteroids or immunosuppressive agents at the time of enrollment&#xD;
&#xD;
         19. Immunodeficiency disease for which immunosuppressive therapy would be contraindicated&#xD;
             according to best medical judgment&#xD;
&#xD;
         20. Pregnancy or lactation&#xD;
&#xD;
         21. For persons of child-bearing potential or impregnating potential, unwillingness to use&#xD;
             appropriate birth control (abstinence, combination barrier and spermicide, hormonal,&#xD;
             or intrauterine device) for the next 18 months or plans to become a biological parent&#xD;
             within the next 18 months.&#xD;
&#xD;
             * In the UK, use of combination barrier and spermicide alone does not meet birth&#xD;
             control requirements.&#xD;
&#xD;
             † UK female study participants must use highly effective methods of contraception.&#xD;
&#xD;
             UK male study participants must use condoms for at least 6 months after the end of&#xD;
             study treatment and their female partners of child-bearing potential are recommended&#xD;
             to use highly effective contraception for the same duration. In addition, male&#xD;
             participants should not donate semen during therapy or for 6 months following&#xD;
             discontinuation of study treatment.&#xD;
&#xD;
         22. Medical problems or drug or alcohol dependence problems sufficient to prevent&#xD;
             adherence to treatment and study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas A Jabs, MD MBA</last_name>
    <role>Study Chair</role>
    <affiliation>CCTand Evidence Synthesis, JHU, Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet T Holbrook, PhD MPH</last_name>
    <phone>443-287-5791</phone>
    <email>jholbro1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth A Sugar, PhD</last_name>
    <email>esugar2@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jules Stein Eye Institute, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Cherian</last_name>
      <phone>310-794-5604</phone>
      <email>NCherian@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caleb Ebert, MPH</last_name>
      <phone>415-476-6687</phone>
      <email>caleb.ebert@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nisha Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Huerta</last_name>
      <phone>305-326-6348</phone>
      <email>c.huerta1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Janet Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alcides Fernandes, MD</last_name>
      <phone>404-778-2421</phone>
      <email>afilho@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ghazala O'Keefe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chisomo Mwale</last_name>
      <phone>312-695-2567</phone>
      <email>chisomo.mwale@nm.org</email>
    </contact>
    <investigator>
      <last_name>Anjum Koreishi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preminder (Daisy) Pacelli</last_name>
      <phone>312-563-5537</phone>
      <email>preminder_pacelli@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Pauline T Merrill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacy Flanagan, BA</last_name>
      <phone>319-467-5184</phone>
      <email>lacy-flanagan@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>James Folk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Sun</last_name>
      <phone>410-502-1873</phone>
      <email>ksun11@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Bryn Burkholder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Eye Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Sherry</last_name>
      <phone>301-435-4529</phone>
      <email>sherryp@nei.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Shipla Kodati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredyth Parsons</last_name>
      <phone>617-314-2703</phone>
      <email>mparsons@eyeboston.com</email>
    </contact>
    <investigator>
      <last_name>Lana M Rifkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System, Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Campbell</last_name>
      <phone>734-936-0138</phone>
      <email>pamtitus@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Susan G Elner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandy Quirin</last_name>
      <email>squirin@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Lynn Hassman, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Giron</last_name>
      <phone>215-662-9393</phone>
      <email>Alexis.Giron@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Nirali Bhatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidAtlantic Retina, Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Kenney</last_name>
      <phone>215-928-3092</phone>
      <email>bkenney@midatlanticretina.com</email>
    </contact>
    <investigator>
      <last_name>James P Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Dahlstrom</last_name>
      <phone>412-647-3434</phone>
      <email>dahlstromrj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Marie-Helene Errera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Walden</last_name>
      <phone>615-345-8912</phone>
      <email>lwalden@tnretina.com</email>
    </contact>
    <investigator>
      <last_name>Akshay Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Nicholson</last_name>
      <phone>615-936-0971</phone>
      <email>crystal.nicholson@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Saige Wilkins</last_name>
      <phone>619-936-1474</phone>
      <email>saige.wilkins@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sapna Gangaputra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsey Moore</last_name>
      <phone>713-524-3434</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Rosa Y Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah, Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberley Wegner, BS, CRC</last_name>
      <phone>801-581-6265</phone>
      <email>kimberley.wegner@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Albert Vitale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington, Medicine Eye Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Luttrell</last_name>
      <phone>206-520-9728</phone>
      <email>luttri@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kathryn Pepple, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Australia</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thuy Chau</last_name>
      <phone>+61 3 9929 8087</phone>
      <email>thuy.chau@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Lyndell Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Mustafic</last_name>
      <phone>+61 2 9362 7300</phone>
      <email>nina.mustafic@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Peter McCluskey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3S5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Delpech</last_name>
      <phone>(514)934-1934</phone>
      <phone_ext>36814</phone_ext>
      <email>isabelle.delpech@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Deschenes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire L Arthur</last_name>
      <phone>+441213718757</phone>
      <email>claire.arthur@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Alastair Denniston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospital NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicci Hawes</last_name>
      <phone>01274 27 6376</phone>
      <email>nicola.hawes@bthft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Helen Devenport</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Tunrbull</last_name>
      <phone>01223 586526</phone>
      <email>paula.turnbull@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Erika Damato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Betteridge</last_name>
      <email>Carol.Betteridge@uhl-tr.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Rybicki</last_name>
      <email>lauren.rybicki@uhl-tr.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Periyasamy Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 9EL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flora Kakanou</last_name>
      <email>flora.kakanou@nhs.net</email>
    </contact>
    <investigator>
      <last_name>William Tucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A public use dataset corresponding to the primary manuscript and compliant with HIPAA regulations will be prepared within 1 year of completion of data collection. An encrypted data set containing de-identified data, a data dictionary and other study documentation (e.g. protocol and study manuals) will be provide after the data use agreement has been executed (see access criteria below).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>One year after completion of data collection, the data set will be available upon request .</ipd_time_frame>
    <ipd_access_criteria>Requests for access to data will be reviewed by the Executive Committee to confirm oversight authority approval (e.g. IRB approval) and a minimum standard of scientific merit. Once a request is approved, the investigator will be required to sign a data use agreement approved by the Johns Hopkins Bloomberg School of Public Health Office of Research Administration. An encrypted data set containing de-identified data, a data dictionary and other study documentation (e.g. protocol and study manuals) will be provide after the data use agreement has been executed.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

